menu
    • menu

    Company profile for Innorna

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    InnoRNA is a platform-based biotechnology company focused on developing innovative mRNA and LNP technologies to produce therapeutic proteins rapidly and accurately in cells. Faced with the challenge of delivering mRNA into the right cells, the existing carriers have been unable to maximize the potential of mRNA as a therapeutic tool to generate disease-fighting proteins. InnoRNA developed the proprietary Diversity-Oriented LNP...
    InnoRNA is a platform-based biotechnology company focused on developing innovative mRNA and LNP technologies to produce therapeutic proteins rapidly and accurately in cells. Faced with the challenge of delivering mRNA into the right cells, the existing carriers have been unable to maximize the potential of mRNA as a therapeutic tool to generate disease-fighting proteins. InnoRNA developed the proprietary Diversity-Oriented LNP platform to deliver mRNA safely and effectively into the cell of interest. The commercialization of this innovation presents a revolutionary step towards delivering effective and safe clinical mRNA treatments.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    InnornaHongKong Flag
    Country
    Country
    Hong Kong
    Address
    Address
    Rm 222, 12 W Science and Technology West Avenue, Phase 3, HKSTP, Shatin, HKSAR
    Telephone
    Telephone
    +852 3520 2228
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.innorna.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innorna Advances Mrna Therapy For Chronic Metabolic Diseases
    Innorna Advances Mrna Therapy For Chronic Metabolic Diseases

    17 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innorna-announces-fda-clearance-of-ind-for-in026-advancing-mrna-based-therapies-into-chronic-metabolic-diseases-302715526.html

    PR NEWSWIRE
    17 Mar 2026
    Share Share
    INNORNA Completes Phase II for Bivalent RSV mRNA Vaccine IN006
    INNORNA Completes Phase II for Bivalent RSV mRNA Vaccine IN006

    10 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250910965047/en/INNORNA-Completes-Phase-II-Enrollment-and-Vaccination-of-Bivalent-RSV-mRNA-Vaccine-IN006

    BUSINESSWIRE
    10 Sep 2025
    Share Share
    Innorna gets FDA Rare Pediatric Disease, Orphan Drug Designations
    Innorna gets FDA Rare Pediatric Disease, Orphan Drug Designations

    27 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250427120055/en/Innorna-Announces-FDA-Rare-Pediatric-Disease-and-Orphan-Drug-Designations-Granted-to-IN013-for-Treatment-of-Wilson-Disease

    BUSINESSWIRE
    27 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search